Table 2 Proportions of patients with prescription medication^a

N

6238

7501

8396

5343

4817

4807

4115

 21–24 months preop

1771

(28.4% [27.3–29.5])

2456

(32.7%[31.7–33.8])

2766

(32.9% [31.9–34.0])

1461

(27.3% [26.2–28.5])

1472

(30.6% [29.3–31.9])

1436

(29.9% [28.6–31.2])

1319

(32.1% [30.6–33.5])

 0–3 months preop

3013

(48.3% [47.1–49.5])

3045

(40.6% [39.5–41.7])

3862

(46.0% [44.9–47.1])

2196

(41.1% [39.8–42.4])

2162

(44.9% [43.5–46.3])

2135

(44.4% [43.0–45.8])

1761

(42.8% [41.3–44.3])

 21–24 months postop

1429

(22.9% [21.9–24.0])

2253

(30.0% [29.0–31.1])

2539

(30.2% [29.3–31.2])

1143

(21.4% [20.3–22.5])

1226

(25.5% [24.2–26.7])

1254

(26.1% [24.9–27.3])

1202

(29.2% [27.8–30.6])

 21–24 months preop

277

(4.4%[3.9–5.0])

390

(5.2% [4.7–5.7])

487

(5.8% [5.3–6.3])

180

(3.4% [2.9–3.9])

161

(3.3% [2.8–3.9])

222

(4.6% [4.0–5.2])

284

(6.9% [6.1–7.7])

 0–3 months preop

870

(13.9% [13.1–14.8])

894

(11.9% [11.2–12.7])

1203

(14.3% [13.6–15.1])

561

(10.5% [9.7–11.3])

439

(9.1% [8.3–9.9])

628

(13.1% [12.1–14.0])

697

(16.9% [15.8–18.1])

 21–24 months postop

546

(8.8% [8.1–9.5])

857

(11.4% [10.7–12.2])

1023

(12.2% [11.5–12.9])

380

(7.1% [6.4–7.8])

313

(6.5% [5.8–7.2])

462

(9.6% [8.8–10.4])

628

(15.3% [14.2–16.4])

 21–24 months preop

1387

(22.2% [21.1–23.3])

1916

(25.5% [24.6–26.5])

2125

(25.3% [24.4–26.2])

1178

(22.0% [20.9–23.2])

1224

(25.4% [24.2–26.6])

1139

(23.7% [22.5–24.9])

940

(22.8% [21.6–24.1])

 0–3 months preop

2095

(33.6% [32.4–34.8])

1983

(26.4% [25.4–27.4])

2544

(30.3% [29.3–31.3])

1534

(28.7% [27.5–29.9])

1664

(34.5% [33.2–35.9])

1455

(30.3% [30.0–31.6])

959

(23.3% [22.0–24.6])

 21–24 months postop

749

(12.0% [11.2–12.8])

1168

(15.6% [14.8–16.4])

1276

(15.2% [14.4–16.0])

641

(12.0% [11.1–12.9])

803

(16.7% [15.6–17.7])

675

(14.0% [13.1–15.0])

439

(10.7% [9.7–11.6])

 21–24 months preop

266

(4.3% [3.8–4.8])

397

(5.3% [4.8–5.8])

431

(5.1% [4.7–5.6])

232

(4.3% [3.8–4.9])

233

(4.8%4.2–5.4])

224

(4.7% [4.1–5.3])

206

(5.0% [4.3–5.7])

 0–3 months preop

850

(13.6% [12.8–14.5])

660

(8.8% [8.2–9.4])

963

(11.5% [10.8–12.2])

547

(10.2% [9.4–11.1])

588

(12.2% [11.3–13.1])

488

(10.2% [9.3–11.0])

434

(10.5% [9.6–11.5])

 21–24 months postop

334

(5.4% [4.8–5.9])

571

(7.6% [7.0–8.2])

631

(7.5% [7.0–8.1])

274

(5.1% [4.5–5.7])

295

(6.1% [5.5–6.8])

305

(6.3% [5.7–7.0])

305

(7.4% [6.6–8.2])

 21–24 months preop

7

(0.1% [0.03–0.2])

25

(0.3% [0.2–0.5])

23

(0.3% [0.2–0.4])

9

(0.2% [0.1–0.3])

10

(0.2% [0.1–0.3])

10

(0.2% [0.1–0.3])

12

(0.3% [0.1–0.5])

 0–3 months preop

29

(0.5% [0.3–0.6])

29

(0.4% [0.3–0.5])

35

(0.4% [0.3–0.6])

23

(0.4% [0.3–0.6])

18

(0.4% [0.2–0.6])

22

(0.5% [0.3–0.7])

18

(0.4% [0.2–0.6])

 21–24 months postop

15

(0.2% [0.1–0.4])

31

(0.4% [0.3–0.6])

35

(0.4% [0.3–0.6)

11

(0.2% [0.1–0.3])

12

(0.2% [0.1–0.4])

16

(0.3% [0.2–0.5])

18

(0.4% [0.2–0.6])

 21–24 months preop

144

(2.3% [1.9–2.7])

233

(3.1% [2.7–3.5])

290

(3.5% [3.1–3.8])

87

(1.6% [1.3–2.0])

145

(3.0% [2.5–3.5])

126

(2.6% [2.2–3.1])

106

(2.6% [2.1–3.1])

 0–3 months preop

192

(3.1% [2.7–3.5])

262

(3.5% [3.1–3.9])

334

(4.0% [3.6–4.4])

120

(2.2% [1.9–2.6])

184

(3.8% [3.3–4.4])

154

(3.2% [2.7–3.7])

116

(2.8% [2.3–3.3])

 21–24 months postop

181

(2.9% [2.5–3.3])

317

(4.2% [3.8–4.7])

370

(4.4% [4.0–4.9)

128

(2.4% [2.0–2.8])

175

(3.6% [3.1–4.2])

165

(3.4% [2.9–4.0])

158

(3.8% [3.3–4.4])